CAR T-cell therapy for relapsed T-cell leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase trial tests a lab-made immune cell treatment (CAR T-cells) aimed at T-cell leukemia that has come back or did not respond. It may help by targeting leukemia cells with a specific marker (CD7), especially in patients who failed standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your leukemia is T-lineage acute lymphoblastic leukemia/lymphoma that has relapsed or is refractory after treatment
- You have measurable disease after treatment (for example, abnormal cells seen in bone marrow or cerebrospinal fluid)
- Your lungs work well enough: mild or no breathing trouble (Grade 1 or less) and oxygen level above 95% on room air
- Your heart pumping function is strong enough based on an ultrasound (echocardiogram)
- You can carry out daily activities at a moderate level (Karnofsky or Lansky score at least 50)
- Your leukemia cells have very high CD7 levels (over 99%) for the anti-CD7 CAR T-cell dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving you a special kind of immune cell, called a CAR T cell, can help fight your B-cell leukemia or lymphoma that has come back or not gone away with standard treatments. The cells are made from your own blood and designed to attack the cancer cells that carry a marker called CD19.
This trial tests a new type of immune therapy called CAR T-cells (engineered to find and attack a protein called CD19 on leukemia cells) for children whose acute lymphoblastic leukemia has come back or hasn't responded to usual treatments. The goal is to see if these special cells can safely help control the disease.
This trial tests a new treatment using special immune cells (called CAR T cells) that are designed to find and destroy leukemia cells that carry a marker called CD7. It is for people whose T-cell or myeloid leukemia has returned or not responded to standard treatments.
This trial tests a new type of immune cell therapy (called CAR-T) that targets two proteins, CD5 and CD7, on the surface of T-cell leukemia or lymphoma cells. It may be an option for people whose cancer came back or didn't respond to standard treatment.
This trial tests whether specially designed immune cells (CAR T cells) that target CD19 can help adults whose B-cell acute lymphoblastic leukemia has not responded to standard treatments or has returned. The cells are made from your own blood and given back to you after a short chemotherapy preparation.
This trial studies a type of immune therapy (CAR T-cells) for people whose leukemia or lymphoma has come back or did not respond after at least two treatment attempts. It aims to improve outcomes in carefully selected patients who can safely receive the treatment.
Hear when a new Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.